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Objective: To compare autonomic function of subjects with Parkinson’s disease (PD) and essential tremor
(ET) relative to controls.
Background: It has been reported that patients with PD have autonomic dysfunction while no literature
exists regarding autonomic function in ET.
Methods: Subjects with PD, ET, and controls had autonomic function measured using the SCOPA-
Autonomic questionnaire, with the total and domain scores transformed to a scale of 0e100 points.
Results: 62 subjects with PD, 84 with ET, and 291 controls were included. Women were more prevalent in
control (69%) compared to PD (44%) and ET (44%) groups, and mean age was signiﬁcantly younger in PD
(73 yrs) and older in ET (83) compared to controls (81). The mean SCOPA-Aut Total score in PD was
signiﬁcantly higher than controls, with no difference in ET. No autonomic dysfunction was found in any
domain in ET but in PD there were signiﬁcant abnormalities in gastrointestinal, cardiovascular, urinary,
and thermoregulatory domains. Individual question data revealed a signiﬁcantly higher percentage of
subjects with dysfunction on 11/23 questions in the PD group but only 1 question (sialorrhea) in the ET
group compared with controls.
Conclusion: Autonomic scores, particularly gastrointestinal, cardiovascular, urinary, and thermoregula-
tory were increased in patients with PD, as assessed by SCOPA-Aut. Patients with ET did not exhibit
autonomic dysfunction, with the exception of sialorrhea.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
The role of non-motor symptoms in patients with movement
disorders is an area gaining increasing recognition. The non-motor
symptoms of Parkinson’s disease (PD), which include cognitive,. Driver-Dunckley).
Y-NC-ND license.psychiatric, autonomic, sleep, and sensory disorders, can be quite
signiﬁcant [1e3]. It has been suggested that themost common non-
motor symptoms of PD are autonomic, and that autonomic
dysfunction is correlated with poor health related quality of life [4].
Various autonomic symptoms have been described in PD.
Gastrointestinal dysfunction positively correlated with increasing
disease severity [5]. Cardiovascular autonomic dysfunction, espe-
cially orthostatic hypotension, may have a prevalence of up to 58%
Table 1
Demographics and SCOPA-autonomic total and domain scores transformed to
a 0e100 scale.
PD ET Control
N 62 84 291
Female 44%a 44%a 69%
Age (yrs); mean  SD 72.9  8.8a 82.8  6.6b 80.5  7.9
SCOPA-Aut (0e100); mean
Total 25a 17 16
Gastrointestinal 24a 12 10
Urinary 34b 30 28
Cardiovascular 9b 4 5
Thermoregulatory 16b 13 12
Pupillomotor 21 17 21
Sexual e Men 61 57 49
Sexual eWomen 32 21 25
a P < .001 vs Control.
b P < .05 vs Control.
Table 2
SCOPA-Aut score greater than zero.
PD ET Control
Swallowing/Choking 32/60 (53%)a 21/84 (25%) 63/290 (22%)
Sialorrhea 50/62 (81%) a 36/84 (43%)b 72/287 (25%)
Dysphagia 25/61 (41%) a 13/84 (15%) 56/289 (19%)
Early abdominal fullness 24/58 (41%) b 17/78 (22%) 63/284 (22%)
Constipation 39/62 (63%) a 27/83 (33%) 90/286 (31%)
Straining for defecation 43/58 (74%) b 42/83 (51%) 151/284 (53%)
Fecal incontinence 8/60 (13%) 19/84 (23%) 44/285 (15%)
Urinary urgency 41/62 (66%) c 43/83 (52%) 150/288 (52%)
Urinary incontinence 37/62 (60%) 40/83 (48%) 143/288 (50%)
Incomplete emptying 33/61 (54%) 37/84 (44%) 121/290 (42%)
Weak stream of urine 33/61 (54%) 48/84 (57%) 138/291 (47%)
Frequency 50/61 (82%) 66/83 (80%) 221/289 (76%)
Nocturia 61/62 (98%) 79/83 (95%) 271/290 (93%)
Lightheaded standing up 24/61 (39%) a 14/84 (17%) 56/287 (20%)
Lightheaded standing for
some time
17/62 (27%) b 8/84 (10%) 42/290 (14%)
Syncope 3/61 (5%) 1/84 (1%) 5/285 (2%)
Hyperhidrosis during the day 21/62 (34%) c 15/84 (18%) 64/287 (22%)
Hyperhidrosis during the night 21/61 (34%) c 25/84 (30%) 66/291 (23%)
Cold intolerance 22/59 (37%) 26/83 (31%) 95/287 (33%)
Heat intolerance 27/59 (46%) 24/81 (30%) 95/285 (33%)
Oversensitive to bright light 31/61 (51%) 31/84 (37%) 132/289 (46%)
Erection problem e Male 30/32 (94%) 27/32 (84%) 56/70 (80%)
Ejaculation problem e Male 26/31 (84%) 24/30 (80%) 42/58 (72%)
Vaginal lubrication e Female 9/11 (82%) 1/4 (25%) 24/45 (53%)
Problem with orgasm e Female 7/11 (64%) 4/4 (100%)c 18/40 (45%)
a P  .001.
b P < .01.
c P  .05 vs Control.
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neous symptoms, such as hypohydrosis or hyperhydrosis, have
been reported in PD patients, and correlate with other symptoms of
autonomic dysfunction [8]. Sexual dysfunction has also been
extensively documented early in the description of the non-motor
symptoms of PD [9]. Thus, a large body of literature exits describing
autonomic dysfunction in PD.
Despite extensive research on autonomic dysfunction in PD,
a thorough literature review did not reveal research regarding
autonomic dysfunction in the most common movement disorder,
essential tremor (ET). For years, a linkage between PD and ET has
been debated [10e12]. In a continued effort to study these disor-
ders comparing non-motor symptoms may be critical. Therefore,
the objective of this study is to compare the occurrence of auto-
nomic symptoms in Parkinson’s disease, essential tremor, and
normal controls, using an autonomic dysfunction questionnaire e
the Scale for Outcomes in Parkinson’s disease for Autonomic
Symptoms (SCOPA-Aut).
2. Methods
All subjects were enrolled in the Arizona Parkinson’s Disease Consortium’s
ongoing longitudinal clinicopathological study in the Banner Sun Health Research
Institute Brain and Body Donation Program (SHRI BBDP) [13]. All subjects signed
written informed consent approved by the Institutional Review Board.
All subjects received standardized movement disorder examinations, including
the UPDRS, Hoehn & Yahr staging and tremor rating scales [14e16], and cognitive
examinations as previously described [17]. Subjects with dementia were excluded
from this analysis as accurate completion of the SCOPA-Aut could not be guaranteed.
Clinically probable PD (PD) was diagnosed if the subject had 2 of the 3 cardinal signs
(rest tremor, bradykinesia, cogwheel rigidity), no symptomatic cause, and
a response to dopaminergic medications. Essential tremor was diagnosed if the
subject had the presence of a grade 2 postural and/or kinetic tremor of the hands or
forearms without identiﬁable secondary cause or other exclusion criteria (e.g.
prominent unilateral tremor, rigidity or bradykinesia). Subjects were examined with
arms outstretched (postural tremor) and on ﬁnger-to-nose-to-ﬁnger testing (kinetic
tremor). Subjects with a tremor score between .5 and 2 were also considered ET if
the research evaluations found the tremor was present for at least 3 years, with
similar exclusion criteria, or medical records supported longstanding ET. Subjects
with Parkinson’s disease or other movement disorders were excluded from the ET
group [18]. The control group was deﬁned as subjects without evidence for
a neurodegenerative disorders such as progressive supranuclear palsy, dementia
with Lewy bodies, other forms of parkinsonism or dementia. Categories of medi-
cations were recorded for each subject at each visit. Subjects did not complete any
additional imaging studies.
Autonomic functionwas measured using the SCOPA-Aut questionnaire [19], a 23
question questionnaire divided into six domains. We selected each subject’s most
recent valid SCOPA-Aut result (valid response on >75% of the questions) and linked
them to the closest movement and cognitive examinationwithin 1 year. The SCOPA-
Aut total score and domain scores were transformed to a scale from 0 to 100 points.
Participants were selected from the SHRI BBDP if they had completed the SCOPA-
Aut questionnaire and did not have restless legs syndrome or a neurodegenerative
disease other than PD. Subjects with PD and ET were each compared to the Control
group. Comparisons of mean SCOPA-Aut scores were made by using the two-sample
t test. Means adjusted for use of medicationwere compared by using a general linear
model. The proportions of subjects with a score greater than zerowere compared by
using the Pearson chi-square test. The sample had 80% power (a .05) if the preva-
lence of a characteristic were 60% for PD versus 40% for controls, and had 90% power
if the prevalence of a characteristic were 60% for ET versus 40% for controls.
3. Results
There were 2760 subjects in the database and of these 642 had
a SCOPA-Aut score. 120 subjects were excluded due to a neurode-
generative disorder other than PD, 83 were excluded due to RLS,
and 2 were excluded due to having both ET and PD. Therefore, 62
subjects with PD, 84 with ET, and 291 Controls included in the
analysis. Women were less prevalent in both the PD (44%) and ET
(44%) groups compared to the Control group (69%) (Table 1). The
mean (þSD) age was lower in the PD group (72.9  8.8 yrs) but
higher in the ET group (82.8  6.6) compared to the Control group
(80.5  7.9) (P < .001) (Table 1). The SCOPA-Aut Total score was notassociated with sex or age in the Control group and therefore it was
not necessary to adjust for these when comparing groups. The
mean SCOPA-Aut Total score was 15.8  8.6 for women and
16.7  7.2 for men (95% CI  3.2 to 1.4, P ¼ .43). The correlation
between the SCOPA-Aut Total score and age was only .03 (95%
CI .15 to .08, P ¼ .59).
3.1. Parkinson’s disease
The mean SCOPA-Aut Total score in subjects with PD was higher
than Control subjects (Table 1). Individual question data revealed
a signiﬁcantly higher percentage of subjects with autonomic
symptoms on 11/23 questions in the PD group. The greatest
difference between PD and Control was in the GI domain (Tables 1
and 2). Other categories with greater autonomic symptoms in PD
included urinary, cardiovascular and thermoregulatory complaints
(Tables 1 and 2). There were signiﬁcant correlations between PD




Cholinesterase inhibitor 6/51 (12%) 1/65 (2%) 8/186 (4%)
SSRI 4/51 (8%) 6/65 (9%) 15/186 (8%)
Other antidepressant 7/51 (14%) 7/65 (11%) 16/186 (9%)
Atypical antipsychotic 1/51 (2%) 0/65 (0%) 1/185 (1%)
Typical antipsychotic 1/51 (0%) 0/65 (0%) 0/185 (0%)
Anxiolytic 9/51 (18%) 9/65 (14%) 14/185 (8%)
Sedative hypnotic 3/51 (6%) 11/65 (17%) 13/185 (7%)
Dopaminergic agent 50/51 (98%) 1/65 (2%) 4/186 (2%)
Statin 13/51 (25%) 24/65 (37%) 67/186 (36%)
Vitamin E 8/51 (16%) 7/65 (11%) 25/186 (13%)
NSAID 9/51 (18%) 11/65 (17%) 36/186 (19%)
Estrogen 2/51 (4%) 4/65 (6%) 20/185 (11%)
A. Damian et al. / Parkinsonism and Related Disorders 18 (2012) 1089e1093 1091urinary incontinence, and sensitivity to bright light (Table 3). The
SCOPA-Aut Total score and Gastrointestinal subscale score also had
correlations of at least .25 with Hoehn and Yahr stage. Using the
Uniﬁed Parkinson’s Disease Rating Scale (UPDRS) motor score there
was a signiﬁcant correlation between disease severity and con-
stipation, heat and cold intolerance. Urinary incontinence, syncope,
and hyperhidrosis also had correlations of at least .25 with UPDRS
motor score (data not shown).
Multiple medications were more prevalent in the PD group than
the Control group including dopaminergic drugs, cholinesterase
inhibitors, antidepressants, and sedatives (Table 4). With the
exception of dopaminergic drugs, none of these medications
substantially altered the comparison of autonomic symptoms
between PD and Controls. It is not possible to determine, with the
current data, the overall effect of dopaminergic medications on the
difference in autonomic scores between groups.3.2. Essential tremor
The mean SCOPA-Aut Total score in subjects with ET was not
higher than Control subjects (Table 1). There were also no differ-
ences between groups for any of the subscores (Table 1). Individual
question data revealed a signiﬁcantly higher percentage of subjects
with autonomic symptoms in only 1/23 questions (sialorrhea) in
the ET group compared with controls (Table 2). While there were
more females with orgasm problems by percentage, only four
responded in the ET group making comparison unclear. There were
no signiﬁcant differences in the medications taken between ET and
Control subjects. Only an additional 6% of subjects used antide-
pressant medication in the ET group than in the Control group (PDTable 3
Relationship between Hoehn and Yahr stage and SCOPA-Aut score among subjects
with PD.
N r P
Total (0e100) 56 .25 .06
Gastrointestinal (0e100) 54 .25 .07
Swallowing/Choking 54 .22 .11
Sialorrhea 56 .16 .25
Dysphagia 55 .26 .06
Early abdominal fullness 52 .07 .61
Constipation 56 .16 .25
Straining for defecation 52 .06 .65
Fecal incontinence 54 .13 .36
Urinary (0e100) 55 .30 .03
Urinary urgency 56 .29 .03
Urinary incontinence 56 .42 .001
Incomplete emptying 55 .25 .06
Weak stream of urine 55 .11 .40
Frequency 55 .07 .62
Nocturia 56 .05 .74
Cardiovascular (0e100) 54 .03 .82
Lightheaded standing up 55 .01 .95
Lightheaded standing for some time 56 .05 .73
Syncope 55 .18 .18
Thermoregulatory (0e100) 55 .13 .33
Hyperhidrosis during the day 56 .09 .51
Hyperhidrosis during the night 55 .06 .68
Cold intolerance 53 .03 .82
Heat intolerance 53 .26 .06
Pupillomotor (0e100) 55 .29 .03
Oversensitive to bright light 55 .29 .03
Sexual e Men (0e100) 29 .00 .99
Erection problem 31 .11 .55
Ejaculation problem 30 .12 .52
Sexual eWomen (0e100) 9 .05 .91
Vaginal lubrication 9 .19 .63
Problem with orgasm 9 .14 .7227%, ET 22%, Controls 16%). Adjustment for use of antidepressant
medication did not increase the difference between the ET and
Control groups.4. Discussion
This study conﬁrms the presence of increased autonomic
symptoms in Parkinson’s disease and is the ﬁrst to establish that
autonomic symptoms are essentially not present in subjects with
essential tremor. A strength of this study was the standardized
method used to collect autonomic symptom data amongst the
groups of PD, ET, and control subjects. Autonomic symptoms were
assessed using a validated questionnaire of autonomic dysfunction,
the SCOPA-Aut [19]. The SCOPA-Aut was developed in 2004 by
Visser and colleagues, as a questionnaire tool designed to assess
autonomic symptoms in patients with PD [19]. This group subse-
quently used the SCOPA-Aut to evaluate a large cohort of PD
patients for autonomic ﬁndings, demonstrating increased symp-
toms in patients with PD in all autonomic domains assessed by the
SCOPA-Aut, namely gastrointestinal, urinary, cardiovascular, ther-
moregulatory, pupillomotor, as well as sexual. These authors
further reported that increased age, increased disease severity, as
well as higher doses of dopaminergic medications were associated
with more symptoms of autonomic dysfunction [20]. This instru-
ment has since been independently validated, and found to be an
acceptable, consistent, valid and precise scale in patients with
Parkinson’s disease [21]. However, there has been criticism of this
instrument, reporting a lack of concordance of both overall score
and item scores of cardiovascular and thermoregulatory domains of
the SCOPA-AUT with cardiovascular and skin autonomic function
testing by sympathetic skin response and ReR interval variation
test [22]. Additionally, Rasch analysis of this instrument has sug-
gested that a shorter version and a simpler response schemewould
optimize this test [23]. Nonetheless, the SCOPA-AUT is a simple,
valid, reliable tool for assessing for the presence of autonomic
symptoms.
Our results conﬁrm that compared to a group of control
subjects, PD patients experience increased symptoms in multiple
domains, namely: gastrointestinal, urinary, cardiovascular, and
thermoregulatory. Pupillomotor ﬁndings of oversensitivity to
bright light, as well as sexual symptoms in men, were not signiﬁ-
cantly different in our sample of PD patients relative to controls. In
our sample of PD patients gastrointestinal dysfunction (swallow-
ing/choking, sialorrhea, dysphagia, constipation, straining for
defecation, and fecal incontinence) are the most prevalent of the
autonomic systems affected. This ﬁnding supports prior data sug-
gesting that gastrointestinal symptoms are the most common of
the symptoms of autonomic dysfunction in PD patients [20]. Not all
A. Damian et al. / Parkinsonism and Related Disorders 18 (2012) 1089e10931092individual symptoms assessed by the SCOPA-Aut were found to be
signiﬁcantly different between PD patients and controls. Symptoms
of fecal incontinence, incomplete emptying of urine, frequency of
urination, nocturia, hyperhydrosis during the day and cold intol-
erance were not signiﬁcantly different in our PD group. This is in
contrast to data previously reported by Verbaan et al., which
suggests that all these individual symptoms within the overall
autonomic domains were signiﬁcantly different in PD patients as
compared to controls, with the exception of vaginal lubrication and
problem with orgasm in women [20]. While the signiﬁcance of the
speciﬁc symptoms is challenged by this study, our data suggests, as
does prior literature, that PD patients experience autonomic
dysfunction pervasive to multiple autonomic domains.
Other than sialorrhea, our data found that subjects with ET did
not have signiﬁcant autonomic symptoms. None of the overall
systems measured by the SCOPA-Aut exhibited a statistically
signiﬁcant difference from controls. There have been no previous
reports of autonomic function in ET for comparison. Certain non-
motor manifestations of ET have been reported including respira-
tory disorders [24], cognitive decline [25,26], depression [3], and
anxiety [3]. In a small group of 10 ET patients a cineﬂuorographic
study found slight slowing in esophageal transit and vocal tremor
during speech without evidence of progressive deterioration [27].
This was contrasted with 100 PD patients who showed severely
disordered swallowing and speech function [27]. However, there is
no literature systematically documenting the presence or absence
of other autonomic symptoms in patients with ET.
SCOPA-Aut total score in both our PD and ET patients were not
correlated with age or sex of the patient, which is inconsistent with
prior data suggesting a correlation with age in PD patients [20,21].
In our study, symptoms of urinary urgency, urinary incontinence,
and oversensitivity to bright light were positively correlated with
increasing Hoehn and Yahr stage of PD and some questions corre-
lated with UPDRS motor severity scores. However, one weakness of
this study is that our sample was too small to rule out a correlation
between the other domains tested and greater disease severity.
Prior data has indicated that total SCOPA-Aut scores increased with
increasing disease severity [20,21], and all domain scores, with the
exception of pupillomotor and sexual domains, also increased with
increasing disease severity [20].
The ﬁnding that autonomic dysfunction based on self-report
was not common in ET yet was in PD may add to the discussion
of whether there is a link between ET and PD. One of the earliest
non-motor symptoms in PD is hyposmia/anosmia [28]. Data
regarding hyposmia in ET has been inconsistent with the majority
of studies ﬁnding no association [29e31]. Further studies have
evaluated sleep [32,33], cognitive function [26,34], and other non-
motor features in ET. These studies are conﬂicting regarding non-
motor abnormalities in ET (see recent review paper Ref. [11]).
This study presents another piece of evidence showing a lack of
association of non-motor symptomatology between PD and ET. Our
ﬁndings conﬁrmed the presence of autonomic symptoms in PD,
and with the exception of sialorrhea, found no autonomic symp-
toms in ET.
It is unclear what causes the autonomic symptoms in PD. It has
been demonstrated in PD patients that phosphorylated alpha-
synuclein histopathology is present in the regions of the spinal
cord containing preganglionic autonomic neurons, as well as
within sympathetic ganglia. It has therefore been suggested that
alpha-synuclein histopathology is likely present within end organ
targets of the autonomic nervous system aswell [35]. This study did
in fact also document phosphorylated alpha-synuclein histopa-
thology in the vagus nerve, gastrointestinal system, sciatic nerve
and endocrine system [35]. While to date the histopathology of the
autonomic nervous system has not been studied in ET patients, thelack of autonomic symptoms suggests a lack of underlying
pathology. Thus this suggests that the primary autonomic
pathology demonstrated histopathologically in PD patients does
not exist in patients with ET.
In addition to previously mentioned limitations, this study was
small. Yet the numbers were large enough to ﬁnd signiﬁcant
differences between groups. Another limitation is that the data is
subjective in nature with no objective testing performed and
depression was not assessed.
In summary, these data demonstrate the presence of autonomic
dysfunction in subjects with Parkinson’s disease but not with
essential tremor. Further study of this population, larger groups of
subjects, and objective measurements of autonomic function are
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